Back to search results

Study of BMS-986278 on Heart Rhythm in Healthy Volunteers

This study is looking at how a drug called BMS-986278 affects your heart's electrical activity, specifically something called cardiac repolarization (how your heart's electrical system recharges after each beat). Researchers want to see if BMS-986278 changes this process. You might receive BMS-986278, a placebo (an inactive substance), or Moxifloxacin (another drug used for comparison). The study will measure changes in your heart's electrical activity (called the QT interval) up to Day 13. They are looking for healthy volunteers between 18 and 55 years old. This study is currently recruiting about 32 participants.

Study design
This is an interventional study involving about 32 healthy participants. It compares the effects of BMS-986278, a placebo, and Moxifloxacin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your heart's electrical activity will be measured up to Day 13 of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07422298

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Completed
PHASE1Ages 18–55InterventionalTreatment
Bristol-Myers Squibb
~32 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:BMS-986278PlaceboMoxifloxacin

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
Measured over Up to Day 13
+1 more outcome measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07422298

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Local Institution - 0001

    San Antonio, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female individuals not of childbearing potential and males.
Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments.
18 to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive.

What this trial measures

  • Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)Up to Day 13
  • Placebo-corrected change from baseline QTcF (ΔΔQTcF)Up to Day 13